{"analyses":[{"ciLowerLimit":"0.795","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.874","groupDescription":"Cough","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified analysis. Stratification factors: Sex (male vs female) and ECOG (0 vs 1).","nonInferiorityType":"SUPERIORITY","pValue":"0.3604","paramType":"Hazard Ratio (HR)","paramValue":"1.221","statisticalMethod":"Log Rank"},{"ciLowerLimit":"0.722","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.553","groupDescription":"Pain in Chest","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified analysis. Stratification factors: Sex (male vs female) and ECOG (0 vs 1).","nonInferiorityType":"SUPERIORITY","pValue":"0.7712","paramType":"Hazard Ratio (HR)","paramValue":"1.058","statisticalMethod":"Log Rank"},{"ciLowerLimit":"0.747","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.552","groupDescription":"Pain in Arm or Shoulder","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified analysis. Stratification factors: Sex (male vs female) and ECOG (0 vs 1).","nonInferiorityType":"SUPERIORITY","pValue":"0.6922","paramType":"Hazard Ratio (HR)","paramValue":"1.077","statisticalMethod":"Log Rank"},{"ciLowerLimit":"0.549","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.019","groupDescription":"Dyspnea","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified analysis. Stratification factors: Sex (male vs female) and ECOG (0 vs 1).","nonInferiorityType":"SUPERIORITY","pValue":"0.0650","paramType":"Hazard Ratio (HR)","paramValue":"0.748","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"comment":"Insufficient number of participants with events.","groupId":"OG000","lowerLimit":"16.6","upperLimit":"NA","value":"NA"},{"comment":"Insufficient number of participants with events.","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"20.3"}]}],"title":"Cough"},{"categories":[{"measurements":[{"comment":"Insufficient number of participants with events.","groupId":"OG000","lowerLimit":"10.9","upperLimit":"NA","value":"NA"},{"comment":"Insufficient number of participants with events.","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}],"title":"Pain in Chest"},{"categories":[{"measurements":[{"comment":"Insufficient number of participants with events.","groupId":"OG000","lowerLimit":"8.8","upperLimit":"NA","value":"NA"},{"comment":"Insufficient number of participants with events.","groupId":"OG001","lowerLimit":"9.2","upperLimit":"NA","value":"NA"}]}],"title":"Pain in Arm or Shoulder"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"3.6","upperLimit":"8.8","value":"5.6"},{"comment":"Insufficient number of participants with events.","groupId":"OG001","lowerLimit":"5.5","upperLimit":"NA","value":"NA"}]}],"title":"Dyspnea"}],"denoms":[{"counts":[{"groupId":"OG000","value":"202"},{"groupId":"OG001","value":"201"}],"units":"Participants"}],"description":"TTD according to the EORTC QLQ-C30 and EORTC QLQ-LC13 measures were evaluated in each of the following linearly transformed symptom scores: cough, dyspnea (single item), dyspnea (multi-item subscale), chest pain, or arm/shoulder pain. The linear transformation gives each individual symptom subscale a possible score of 0 to 100. For the symptom to be considered \"deteriorated,\" a score increase of ≥10 points above baseline must be held for at least two consecutive assessments or an initial score increase of ≥10 points is followed by death within 3 weeks from the last assessment. A ≥ 10-point change in the symptoms subscale score is perceived by participants as clinically significant.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received intravenous infusions of placebo in combination with carboplatin to achieve an initial target AUC of 5 mg/mL/min followed by etoposide 100 mg/m\\^2 on Day 1 of every 21-day cycle during the induction phase (Cycles 1-4). On Days 2 and 3 of every 21-day cycle during the induction phase (Cycles 1-4), etoposide 100 mg/m\\^2 was administered alone. Thereafter, participants received maintenance (Cycle 5 onward) placebo on Day 1 of every 21-day cycle until persistent radiographic PD, symptomatic deterioration, intolerable toxicity, withdrawal of consent, death, or study termination by the Sponsor.","id":"OG000","title":"Placebo + Carboplatin + Etoposide"},{"description":"Participants received intravenous infusions of atezolizumab 1200 milligrams (mg) in combination with carboplatin to achieve an initial target area under the concentration-time curve (AUC) of 5 milligrams per milliliter per minute (mg/mL/min) followed by etoposide 100 milligrams per square meter (mg/m\\^2) on Day 1 of every 21-day cycle during the induction phase (Cycles 1-4). On Days 2 and 3 of every 21-day cycle during the induction phase (Cycles 1-4), etoposide 100 mg/m\\^2 was administered alone. Thereafter, participants received maintenance (Cycle 5 onward) atezolizumab 1200 mg on Day 1 of every 21-day cycle until persistent radiographic PD, symptomatic deterioration, intolerable toxicity, withdrawal of consent, death, or study termination by the Sponsor.","id":"OG001","title":"Atezolizumab + Carboplatin + Etoposide"}],"paramType":"MEDIAN","populationDescription":"The ITT population was defined as all randomized participants, regardless of whether the participant received the assigned treatment.","reportingStatus":"POSTED","timeFrame":"Baseline until deterioration per symptom subscale (up to approximately 23 months)","title":"Time to Deterioration (TTD) Per European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ) Core 30 (C30) and Supplemental Lung Cancer Module (QLQ-LC13) in the Global Population","type":"SECONDARY","unitOfMeasure":"Month"}